Point-of-care versus central testing of hemoglobin during large volume blood transfusion.

BACKGROUND: Point-of-care (POC) hemoglobin testing has the potential to revolutionize massive transfusion strategies. No prior studies have compared POC and central laboratory testing of hemoglobin in patients undergoing massive transfusions. METHODS: We retrospectively compared the results of our point-of-care hemoglobin test (EPOC®) to our core laboratory complete blood count (CBC) hemoglobin test (Sysmex XE-5000™) in patients undergoing massive transfusion protocols (MTP) for hemorrhage. One hundred seventy paired samples from 90 patients for whom MTP was activated were collected at a single, tertiary care hospital between 10/2011 and 10/2017. Patients had both an EPOC® and CBC hemoglobin performed within 30 min of each other during the MTP. We assessed the accuracy of EPOC® hemoglobin testing using two variables: interchangeability and clinically significant differences from the CBC. The Clinical Laboratory Improvement Amendments (CLIA) proficiency testing criteria defined interchangeability for measurements. Clinically significant differences between the tests were defined by an expert panel. We examined whether these relationships changed as a function of the hemoglobin measured by the EPOC® and specific patient characteristics. RESULTS: Fifty one percent (86 of 170) of paired samples\u27 hemoglobin results had an absolute difference of ≤7 and 73% (124 of 170) fell within ±1 g/dL of each other. The mean difference between EPOC® and CBC hemoglobin had a bias of - 0.268 g/dL (p = 0.002). When the EPOC® hemoglobin was \u3c 7 g/dL, 30% of the hemoglobin values were within ±7, and 57% were within ±1 g/dL. When the measured EPOC® hemoglobin was ≥7 g/dL, 55% of the EPOC® and CBC hemoglobin values were within ±7, and 76% were within ±1 g/dL. EPOC® and CBC hemoglobin values that were within ±1 g/dL varied by patient population: 77% for cardiac surgery, 58% for general surgery, and 72% for non-surgical patients. CONCLUSIONS: The EPOC® device had minor negative bias, was not interchangeable with the CBC hemoglobin, and was less reliable when the EPOC® value was \u3c 7 g/dL. Clinicians must consider speed versus accuracy, and should check a CBC within 30 min as confirmation when the EPOC® hemoglobin is \u3c 7 g/dL until further prospective trials are performed in this population

Eliminating Unnecessary Premedications before Outpatient Transfusions

Aims for Improvement Our aim is to eliminate premedication prior to outpatient transfusions in patients without a prior transfusion reaction by 75% within 1 year

Latin American Thyroid Society Recommendations For The Management Of Thyroid Nodules [recomendações Da Sociedade Latino-americana De Tireoide No Manejo De Nódulos Tireoideos]

Several guidelines on diagnosis and treatment of thyroid nodules and cancer have recently been published. However, recommended practices are not always appropriate to different settings or countries. The aim of this consensus was to develop Clinical Guidelines for evaluation and management of patients with thyroid nodules applicable to Latin American countries. The panel was composed by 13 members of the Latin American Thyroid Society involved with research and management of thyroid nodules and cancer from different medical centers in Latin America. The consensus was produced based on the expert opinion of the panel with use of principles of evidence-based medicine. Following a group meeting, a first draft based on the expert opinion of the panel was elaborated and later circulated among panel members for further revision. After revision, this document was submitted to all LATS members for commentaries and considerations and finally revised and refined by the authors. The final recommendations represent state of the art on management of thyroid nodules applied to all Latin American countries. © ABE&M todos os direitos reservados.53911671175Villena, J., Pretell, E., Bocio nodular tóxico en pacientes de zonas yodo deficientes y de la costa (1991) Rev Méd Hered, 2 (4), pp. 149-155Villena, J., Ferrufino, J.C., Klinge, G., Nódulo tireoideo frio. Características clínicas y anatomopatológicas en pacientes migrantes de zonas con deficiencia de yodo y de la costa (1993) Rev Méd Hered, 4 (4), pp. 188-193Harach, H.R., Ceballos, G.A., Thyroid cancer, thyroiditis and dietary iodine: A review based on the Salta, Argentina model (2008) Endocr Pathol, 19 (4), pp. 209-220Pretell, E.A., Delange, F., Hostalek, U., Corigliano, S., Barreda, L., Higa, A.M., Iodine nutrition improves in Latin America (2004) Thyroid, 14 (8), pp. 595-604Harach, H.R., Franssila, K.O., Wasenius, V.M., Occult papillary carcinoma of the thyroid. A "normal" finding in Finland. A systematic autopsy study (1985) Cancer, 56 (3), pp. 531-538Rosai, J., Livolsi, V.A., Sobrinho-Simoes, M., Williams, E.D., Renaming papillary microcarcinoma of the thyroid gland: The Porto proposal (2003) Int J Surg Pathol, 11 (4), pp. 249-251Hay, I.D., Grant, C.S., van Heerden, J.A., Goellner, J.R., Ebersold, J.R., Bergstralh, E.J., Papillary thyroid microcarcinoma: A study of 535 cases observed in a 50-year period (1992) Surgery, 112 (6), pp. 1139-1146Jukkola, A., Bloigu, R., Ebeling, T., Salmela, P., Blanco, G., Prognostic factors in differentiated thyroid carcinomas and their implications for current staging classifications (2004) Endocr Relat Cancer, 11 (3), pp. 571-579Passler, C., Scheuba, C., Prager, G., Kaczirek, K., Kaserer, K., Zettinig, G., Prognostic factors of papillary and follicular thyroid cancer: Differences in an iodine-replete endemic goiter region (2004) Endocr Relat Cancer, 11 (1), pp. 131-139Rossi, R., Roti, E., Trasforini, G., Pansini, G., Cavazzini, L., Zatelli, M.C., Differentiated thyroid cancers 11-20 mm in diameter have clinical and histopathologic characteristics suggesting higher aggressiveness than those ≤ 10 mm (2008) Thyroid, 18 (3), pp. 309-315Curtis, R.E., Rowlings, P.A., Deeg, H.J., Shriner, D.A., Socie, G., Travis, L.B., Solid cancers after bone marrow transplantation (1997) N Engl J Med, 336 (13), pp. 897-904Sippel, R.S., Caron, N.R., Clark, O.H., An evidence-based approach to familial nonmedullary thyroid cancer: Screening, clinical management, and follow-up (2007) World J Surg, 31 (5), pp. 924-933Pacini, F., Pinchera, A., Giani, C., Grasso, L., Doveri, F., Baschieri, L., Serum thyroglobulin in thyroid carcinoma and other thyroid disorders (1980) J Endocrinol Invest, 3 (3), pp. 283-292Niccoli, P., Wion-Barbot, N., Caron, P., Henry, J.F., de Micco, C., Saint Andre, J.P., Interest of routine measurement of serum calcitonin: Study in a large series of thyroidectomized patients. The French Medullary Study Group (1997) J Clin Endocrinol Metab, 82 (2), pp. 338-341Gagel, R.F., Hoff, A.O., Cote, G.J., Medullary thyroid carcinoma (2005) Werner and Ingbar's the Thyroid: A Fundamental and Clinical Text, pp. 967-988. , In: Lewis E, Robert D, Sidney H, Sidney C, (Eds)., Philadelphia: Lippincott Williams and WilkinsPapini, E., Guglielmi, R., Bianchini, A., Crescenzi, A., Taccogna, S., Nardi, F., Risk of malignancy in nonpalpable thyroid nodules: Predictive value of ultrasound and color-Doppler features (2002) J Clin Endocrinol Metab, 87 (5), pp. 1941-1946Camargo, R.Y., Tomimori, E.K., Knobel, M., Medeiros-Neto, G., Preoperative assessment of thyroid nodules: Role of ultrasonography and fine needle aspiration biopsy followed by cytology (2007) Clinics, 62 (4), pp. 411-418Kang, H.W., No, J.H., Chung, J.H., Min, Y.K., Lee, M.S., Lee, M.K., Prevalence, clinical and ultrasonographic characteristics of thyroid incidentalomas (2004) Thyroid, 14 (1), pp. 29-33Shimura, H., Haraguchi, K., Hiejima, Y., Fukunari, N., Fujimoto, Y., Katagiri, M., Distinct diagnostic criteria for ultrasonographic examination of papillary thyroid carcinoma: A multicenter study (2005) Thyroid, 15 (3), pp. 251-258Cappelli, C., Castellano, M., Pirola, I., Cumetti, D., Agosti, B., Gandossi, E., The predictive value of ultrasound findings in the management of thyroid nodules (2007) Qjm, 100 (1), pp. 29-35Holden, A., The role of colour and duplex Doppler ultrasound in the assessment of thyroid nodules (1995) Australas Radiol, 39 (4), pp. 343-349Papini, E., Guglielmi, R., Bianchini, A., Crescenzi, A., Taccogna, S., Nardi, F., Risk of malignancy in nonpalpable thyroid nodules: Predictive value of ultrasound and color-Doppler features (2002) J Clin Endocrinol Metab, 87 (5), pp. 1941-1946Chammas, M.C., Gerhard, R., de Oliveira, I.R., Widman, A., de Barros, N., Durazzo, M., Thyroid nodules: Evaluation with power Doppler and duplex Doppler ultrasound (2005) Otolaryngol Head Neck Surg, 132 (6), pp. 874-882Frates, M.C., Benson, C.B., Doubilet, P.M., Cibas, E.S., Marqusee, E., Can color Doppler sonography aid in the prediction of malignancy of thyroid nodules? (2003) J Ultrasound Med, 22 (2), pp. 127-131Rago, T., Vitti, P., Chiovato, L., Mazzeo, S., de Liperi, A., Miccoli, P., Role of conventional ultrasonography and color flow-doppler sonography in predicting malignancy in 'cold' thyroid nodules (1998) Eur J Endocrinol, 138 (1), pp. 41-46Lyshchik, A., Moses, R., Barnes, S.L., Higashi, T., Asato, R., Miga, M.I., Quantitative analysis of tumor vascularity in benign and malignant solid thyroid nodules (2007) J Ultrasound Med, 26 (6), pp. 837-846Tamsel, S., Demirpolat, G., Erdogan, M., Nart, D., Karadeniz, M., Uluer, H., Power Doppler US patterns of vascularity and spectral Doppler US parameters in predicting malignancy in thyroid nodules (2007) Clin Radiol, 62 (3), pp. 245-251Pacini, F., Burroni, L., Ciuoli, C., di Cairano, G., Guarino, E., Management of thyroid nodules: A clinicopathological, evidence-based approach (2004) Eur J Nucl Med Mol Imaging, 31 (10), pp. 1443-1449Kim, T.Y., Kim, W.B., Ryu, J.S., Gong, G., Hong, S.J., Shong YK. 18F-fluorodeoxyglucose uptake in thyroid from positron emission tomogram (PET) for evaluation in cancer patients: High prevalence of malignancy in thyroid PET incidentaloma (2005) Laryngoscope, 115 (6), pp. 1074-1078Danese, D., Sciacchitano, S., Farsetti, A., Andreoli, M., Pontecorvi, A., Diagnostic accuracy of conventional versus sonography-guided fine-needle aspiration biopsy of thyroid nodules (1998) Thyroid, 8 (1), pp. 15-21de la Serna Saravia, C., Cuellar, F., Accuracy of aspiration cytology in thyroid cancer: A study in 1 institution (2006) Acta Cytol, 50 (4), pp. 384-387Giorgadze, T., Rossi, E.D., Fadda, G., Gupta, P.K., Livolsi, V.A., Baloch, Z., Does the fine-needle aspiration diagnosis of "Hurthle-cell neoplasm/follicular neoplasm with oncocytic features" denote increased risk of malignancy? (2004) Diagn Cytopathol, 31 (5), pp. 307-312Niepomniszcze, H., Garcia, A., Faure, E., Castellanos, A., del Carmen Zalazar, M., Bur, G., Long-term follow-up of contralateral lobe in patients hemithyroidectomized for solitary follicular adenoma (2001) Clin Endocrinol (oxf), 55 (4), pp. 509-513Alcantara-Jones, D.M., Araujo, L.M., Almeida, A.M., Jones, D.A., Cardoso, L.J., Passos, M.C., Percutaneous ethanol injection for the treatment of thyroid nodules (2006) Arq Bras Endocrinol Metabol, 50 (1), pp. 97-104Lippi, F., Ferrari, C., Manetti, L., Rago, T., Santini, F., Monzani, F., Treatment of solitary autonomous thyroid nodules by percutaneous ethanol injection: Results of an Italian multicenter study. The Multicenter Study Group (1996) J Clin Endocrinol Metab, 81 (9), pp. 3261-3264Hegedüs, L., Hansen, B.M., Knudsen, N., Hansen, J.M., Reduction of size of thyroid with radioactive iodine in multinodular non-toxic goitre (1988) Bmj, 297 (6649), pp. 661-662Huysmans, D., Hermus, A., Edelbroek, M., Barentsz, J., Corstens, F., Kloppenborg, P., Radioiodine for nontoxic multinodular goiter (1997) Thyroid, 7 (2), pp. 235-239Nygaard, B., Hegedus, L., Ulriksen, P., Nielsen, K.G., Hansen, J.M., Radioiodine therapy for multinodular toxic goiter (1999) Arch Intern Med, 159 (12), pp. 1364-1368Huysmans, D.A., Hermus, A.R., Corstens, F.H., Barentsz, J.O., Kloppenborg, P.W., Large, compressive goiters treated with radioiodine (1994) Ann Intern Med, 121 (10), pp. 757-762Nygaard, B., Soes-Petersen, U., Hoilund-Carlsen, P.F., Veje, A., Holst, P.E., Vestergaard, A., Improvement of upper airway obstruction after 131I-treatment of multinodular nontoxic goiter evaluated by flow volume loop curves (1996) J Endocrinol Invest, 19 (2), pp. 71-75Nygaard, B., Faber, J., Hegedus, L., Acute changes in thyroid volume and function following 131I therapy of multinodular goitre (1994) Clin Endocrinol (oxf), 41 (6), pp. 715-718Huysmans, D.A., Nieuwlaat, W.A., Erdtsieck, R.J., Schellekens, A.P., Bus, J.W., Bravenboer, B., Administration of a single low dose of recombinant human thyrotropin significantly enhances thyroid radioiodide uptake in nontoxic nodular goiter (2000) J Clin Endocrinol Metab, 85 (10), pp. 3592-3596Nieuwlaat, W.A., Hermus, A.R., Sivro-Prndelj, F., Corstens, F.H., Huysmans, D.A., Pretreatment with recombinant human TSH changes the regional distribution of radioiodine on thyroid scintigrams of nodular goiters (2001) J Clin Endocrinol Metab, 86 (11), pp. 5330-5336Nieuwlaat, W.A., Huysmans, D.A., van den Bosch, H.C., Sweep, C.G., Ross, H.A., Corstens, F.H., Pretreatment with a single, low dose of recombinant human thyrotropin allows dose reduction of radioiodine therapy in patients with nodular goiter (2003) J Clin Endocrinol Metab, 88 (7), pp. 3121-3129Duick, D.S., Baskin, H.J., Utility of recombinant human thyrotropin for augmentation of radioiodine uptake and treatment of nontoxic and toxic multinodular goiters (2003) Endocr Pract, 9 (3), pp. 204-209Silva, M.N., Rubio, I.G., Romao, R., Gebrin, E.M., Buchpiguel, C., Tomimori, E., Administration of a single dose of recombinant human thyrotrophin enhances the efficacy of radioiodine treatment of large compressive multinodular goitres (2004) Clin Endocrinol (oxf), 60 (3), pp. 300-308Albino, C.C., Mesa Jr., C.O., Olandoski, M., Ueda, C.E., Woellner, L.C., Goedert, C.A., Recombinant human thyrotropin as adjuvant in the treatment of multinodular goiters with radioiodine (2005) J Clin Endocrinol Metab, 90 (5), pp. 2775-2780Friguglietti, C.U., Lin, C.S., Kulcsar, M.A., Total thyroidectomy for benign thyroid disease (2003) Laryngoscope, 113 (10), pp. 1820-1826Rezzonico, J., Rezzonico, M., Pusiol, E., Pitoia, F., Neipomniszcze, H., Introducing the thyroid gland as another victim of the insulin resistance syndrome (2008) Thyroid, 18 (4), pp. 461-464Vella, V., Sciacca, L., Pandini, G., Mineo, R., Squatrito, S., Vigneri, R., The IGF system in thyroid cancer: New concepts (2001) Mol Pathol, 54 (3), pp. 121-124Rezzonico, J., Rezzonico, M., Pusiol, E., Pitoia, F., Neipomniszcze, H., 2008 Metformin treatment of benign thyroid nodules in euthytoid patients with insulin resistance (2008) Diabetes Vasc Dis Reas, 5, p. 223Papini, E., Guglielmi, R., Bizzarri, G., Graziano, F., Bianchini, A., Brufani, C., Pacella, S., Pacella, C.M., Treatment of benign cold thyroid nodules: A randomized clinical trial of percutaneous lases ablation versus levothyroxine therapy or follow-up (2007) Thyroid, pp. 229-235Spiezia, S., Garberoglio, R., Milone, F., Ramundo, V., Caiazzo, C., Assanti, A.P., Thyroid nodules and related symptoms are stably controlled two years after radiofrequency thermal ablation (2009) Thyroid, 19 (3), pp. 219-225Alexander, E.K., Hurwitz, S., Heering, J.P., Benson, C.B., Frates, M.C., Doubilet, P.M., Natural history of benign solid and cystic thyroid nodules (2003) Ann Intern Med, 138 (4), pp. 315-318Carmeci, C., Jeffrey, R.B., McDougall, I.R., Nowels, K.W., Weigel, R.J., Ultrasound-guided fine-needle aspiration biopsy of thyroid masses (1998) Thyroid, 8 (4), pp. 283-289Ylagan, L.R., Farkas, T., Dehner, L.P., Fine needle aspiration of the thyroid: A cytohistologic correlation and study of discrepant cases (2004) Thyroid, 14 (1), pp. 35-41Hung, W., Anderson, K.D., Chandra, R.S., Kapur, S.P., Patterson, K., Randolph, J.G., Solitary thyroid nodules in 71 children and adolescents (1992) J Pediatr Surg, 27 (11), pp. 1407-1409Yip, F.W., Reeve, T.S., Poole, A.G., Delbridge, L., Thyroid nodules in childhood and adolescence (1994) Aust N Z J Surg, 64 (10), pp. 676-678Hegedus, L., Clinical practice. The thyroid nodule (2004) N Engl J Med, 351 (17), pp. 1764-1771Niedziela, M., Pathogenesis, diagnosis and management of thyroid nodules in children (2006) Endocr Relat Cancer, 13 (2), pp. 427-453Degnan, B.M., McClellan, D.R., Francis, G.L., An analysis of fine-needle aspiration biopsy of the thyroid in children and adolescents (1996) J Pediatr Surg, 31 (7), pp. 903-907Lugo-Vicente, H., Ortiz, V.N., Irizarry, H., Camps, J.I., Pagan, V., Pediatric thyroid nodules: Management in the era of fine needle aspiration (1998) J Pediatr Surg, 33 (8), pp. 1302-1305Corrias, A., Einaudi, S., Chiorboli, E., Weber, G., Crino, A., Andreo, M., Accuracy of fine needle aspiration biopsy of thyroid nodules in detecting malignancy in childhood: Comparison with conventional clinical, laboratory, and imaging approaches (2001) J Clin Endocrinol Metab, 86 (10), pp. 4644-4648Amrikachi, M., Ponder, T.B., Wheeler, T.M., Smith, D., Ramzy, I., Thyroid fine-needle aspiration biopsy in children and adolescents: Experience with 218 aspirates (2005) Diagn Cytopathol, 32 (4), pp. 189-192Gharib, H., Papini, E., Valcavi, R., Baskin, H.J., Crescenzi, A., Dottorini, M.E., Duick, D.S., Zini, M., AACE/AME Task Force on Thyroid Nodules. American Association of Clinical Endocrinologists and Associazione Medici Endocrinologi medical guidelines for clinical practice for the diagnosis and management of thyroid nodules (2006) Endocr Pract, 12 (1), pp. 63-102Wiersinga, W.M., Management of thyroid nodules in children and adolescents (2007) Hormones (athens), 6 (3), pp. 194-199Moosa, M., Mazzaferri, E.L., Outcome of differentiated thyroid cancer diagnosed in pregnant women (1997) J Clin Endocrinol Metab, 82 (9), pp. 2862-286

Follicular thyroid carcinoma invades venous rather than lymphatic vessels

Follicular thyroid carcinoma (FTC) tends to metastasize to remote organs rather than local lymph nodes. Separation of FTC from follicular thyroid adenoma (FTA) relies on detection of vascular and/or capsular invasion. We investigated which vascular markers, CD31, CD34 and D2-40 (lymphatic vessel marker), can best evaluate vascular invasion and why FTC tends to metastasize via blood stream to remote organs. Thirty two FTCs and 34 FTAs were retrieved for evaluation. The average age of patients with FTA was 8 years younger than FTC (p = 0.02). The female to male ratio for follicular neoplasm was 25:8. The average size of FTC was larger than FTA (p = 0.003). Fourteen of 32 (44%) FTCs showed venous invasion and none showed lymphatic invasion, with positive CD31 and CD34 staining and negative D2-40 staining of the involved vessels. The average number of involved vessels was 0.88 ± 1.29 with a range from 0 to 5, and the average diameter of involved vessels was 0.068 ± 0.027 mm. None of the 34 FTAs showed vascular invasion. CD31 staining demonstrated more specific staining of vascular endothelial cells than CD34, with less background staining. We recommended using CD31 rather than CD34 and/or D2-40 in confirming/excluding vascular invasion in difficult cases. All identified FTCs with vascular invasions showed involvement of venous channels, rather than lymphatic spaces, suggesting that FTCs prefer to metastasize via veins to distant organs, instead of lymphatic vessels to local lymph nodes, which correlates with previous clinical observations

BMI, Diet and Female Reproductive Factors as Risks for Thyroid Cancer: A Systematic Review

Background: Thyroid cancer incidence rates have been increasing worldwide but the reason behind this is unclear. Both the increasing use of diagnostic technologies allowing the detection of thyroid cancer and a true increase in thyroid cancer incidence have been proposed. This review assesses the role of body mass index (BMI), diet, and reproductive factors on the thyroid cancer trend. Methods: Epidemiologic studies of the selected risk factors up to June 2010 were reviewed and critically assessed. Results: Among the thirty-seven studies reviewed and despite variation in the risk estimates, most papers supported a small but positive association for BMI (risk estimate range: 1.1–2.3 in males and 1.0–7.4 in females.). Among specific dietary components, there was no consistent association of thyroid cancer risk with iodine intake through fortification (risk estimate range: 0.49–1.6) or fish consumption (risk estimate range 0.6–2.2), nor with diets high in cruciferous vegetables (risk estimate range 0.6–1.9). A small number of studies showed a consistent protective effect of diets high in non-cruciferous vegetable (risk estimate range: 0.71–0.92). Among reproductive factors (pregnancy, parity, number of live births, use of prescription hormones, menstrual cycle regularity, and menopausal status), none were consistently associated with higher thyroid cancer risk. Conclusions: BMI had the strongest link to thyroid cancer risk among those examined. Detailed examinations of populationleve

Effects of supplemented isoenergetic diets varying in cereal fiber and protein content on the bile acid metabolic signature and relation to insulin resistance

Bile acids (BA) are potent metabolic regulators influenced by diet. We studied effects of isoenergetic increases in the dietary protein and cereal-fiber contents on circulating BA and insulin resistance (IR) in overweight and obese adults. Randomized controlled nutritional intervention (18 weeks) in 72 non-diabetic participants (overweight/obese: 29/43) with at least one further metabolic risk factor. Participants were group-matched and allocated to four isoenergetic supplemented diets: control; high cereal fiber (HCF); high-protein (HP); or moderately increased cereal fiber and protein (MIX). Whole-body IR and insulin-mediated suppression of hepatic endogenous glucose production were measured using euglycaemic–hyperinsulinemic clamps with [6-62H2] glucose infusion. Circulating BA, metabolic biomarkers, and IR were measured at 0, 6, and 18 weeks. Under isoenergetic conditions, HP-intake worsened IR in obese participants after 6 weeks (M-value: 3.77 ± 0.58 vs. 3.07 ± 0.44 mg/kg/min, p = 0.038), with partial improvement back to baseline levels after 18 weeks (3.25 ± 0.45 mg/kg/min, p = 0.089). No deleterious effects of HP-intake on IR were observed in overweight participants. HCF-diet improved IR in overweight participants after 6 weeks (M-value 4.25 ± 0.35 vs. 4.81 ± 0.31 mg/kg/min, p = 0.016), but did not influence IR in obese participants. Control and MIX diets did not influence IR. HP-induced, but not HCF-induced changes in IR strongly correlated with changes of BA profiles. MIX-diet significantly increased most BA at 18 weeks in obese, but not in overweight participants. BA remained unchanged in controls. Pooled BA concentrations correlated with fasting fibroblast growth factor-19 (FGF-19) plasma levels (r = 0.37; p = 0.003). Higher milk protein intake was the only significant dietary predictor for raised total and primary BA in regression analyses (total BA, p = 0.017; primary BA, p = 0.011). Combined increased intake of dietary protein and cereal fibers markedly increased serum BA concentrations in obese, but not in overweight participants. Possible mechanisms explaining this effect may include compensatory increases of the BA pool in the insulin resistant, obese state; or defective BA transport